Sensitive, specific and accurate determination of an analyte or biomarker is critical for diagnosis, therapy, drug & vaccine safety. However, the complex nature of sample matrices poses a challenge to obtaining a reliable result, especially for those analytes and biomarkers with low abundance but high significance. For example, IgE-mediated anaphylaxis is life-threatening. Detection of pre-existing allergen-specific IgE can identify individuals at risk. By removing the background of each analyte by dual calibration, our proprietary FocalTuning™ platform and products (US10,914,731B2, 2021; US11,835,517B2, 2023; ZL202080015982.5, 2024) can detect and quantify low level analytes such as polyethylene glycol (PEG) specific IgE.
The features of FocalTuning™ platform
- Patented technology
- Two-level background correction
- Patient-specific background correction
- Matrix-specific background correction
- High sensitivity and accuracy
- Ability to multiplex
- Powerful statistics